mish2575 Joined May 22, 2013 Messages 656 Nov 27, 2013 #1 Its all in the numbers. It was a very small study but the results are amazing. "Patients receiving adalimumab after intestinal resection demonstrated a significantly lower likelihood of endoscopic and clinical recurrence of Crohn’s disease, according to recent study results." "After 2 years of follow-up, endoscopic recurrence — which predicts the likelihood of complications and the potential need for reoperation — was seen at a significantly lower rate in the ADA group (6.3%) than with the AZA (64.7%; OR=0.036; 95% CI, 0.004-0.347) or mesalamine groups (83.3%; OR=0.013; 95% CI, 0.001-0.143)." :dance:
Its all in the numbers. It was a very small study but the results are amazing. "Patients receiving adalimumab after intestinal resection demonstrated a significantly lower likelihood of endoscopic and clinical recurrence of Crohn’s disease, according to recent study results." "After 2 years of follow-up, endoscopic recurrence — which predicts the likelihood of complications and the potential need for reoperation — was seen at a significantly lower rate in the ADA group (6.3%) than with the AZA (64.7%; OR=0.036; 95% CI, 0.004-0.347) or mesalamine groups (83.3%; OR=0.013; 95% CI, 0.001-0.143)." :dance:
Riley Joined Nov 28, 2012 Messages 33 Nov 29, 2013 #2 Thank you for posting that, I just had a resection 2.5 weeks ago and meet with my GI next week about starting back on Humira
Thank you for posting that, I just had a resection 2.5 weeks ago and meet with my GI next week about starting back on Humira
